Pediatric Hematology/Oncology welcomes Dr. Anca Dumitriu!

The division is thrilled to announce the addition of **Dr. Dumitriu** as an assistant professor. Dr. Dumitriu was a former pediatric hematology/oncology fellow with our division. She was honored during her first year of fellowship with the Department of Pediatrics Fellow of the Year award. Dr. Dumitriu will be seeing all types of hematology/oncology patients, and she will further specialize as the physician medical director of our Follow Up After Cancer Treatment (FACT) survivorship clinic.

Currently enrolling for 2 new pediatric thrombosis clinical trials

**A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND EXTRAPOLATED EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT** (Pfizer, Inc.)

This trial involves the use of Apixiban (direct oral anticoagulant agent).

**Inclusion criteria:** Children 5-12 years of age at the time of consent with the presence of an index venous thrombosis event (VTE) which is confirmed by imaging. Index VTE include, but are not limited to, deep vein thrombosis, pulmonary embolus, cerebral sinovenous thrombosis, renal vein thrombosis, portal vein thrombosis, and splanchnic thrombosis.

**PROSPECTIVE EVALUATION OF THE DURATION OF THERAPY FOR THROMBOSIS IN CHILDREN** (All Children’s John Hopkins Medicine and All Children’s Hospital Foundation, a seeded grant from the Hemophilia and Thrombosis Research Society).

**Inclusion Criteria:** Children (birth to <21 years of age) with radiologically-confirmed acute venous thrombosis in the past 30 days that is considered **provoked** (i.e., non-spontaneous) event (e.g.: hospitalization; Central venous catheterization; infection; dehydration; surgery; trauma; immobility; use of estrogen-containing oral contraceptive pills; flare of autoimmune/rheumatologic condition).

Contact Dr. Shayla Bergmann directly if you have any patient with a new clot. **bergmans@musc.edu** 843-812-5682.

Thanks to our entire team- Pediatric Cancer Program again recognized as a top program by US News & World Report!